The FDA approved a new oral GLP-1 this month called Foundayo, and for the first time in years there's something genuinely different to offer patients who won't do injections.
Not better across the board. Different. The distinction matters. Orforglipron, the active ingredient, is a non-peptide GLP-1 receptor agonist, which means it doesn't need the same narrow absorption window as oral semaglutide. You can take it with food, without food, at whatever time fits your day. For a specific group of patients, that removes the main obstacle that was keeping them from starting. For everyone else, the medications that already exist are still producing stronger results. Worth saying upfront, because the approval news tends to generate more enthusiasm than that nuance supports.
I should also note: we're weeks into prescribing this outside a trial. The ATTAIN-1 trial ran 36 weeks in a controlled setting. What I'll see in my office over the next year, how insurance covers it, how adherence actually holds up outside a trial, whether the side effect profile in practice looks like the published data, is still an open question. What follows is what the data says. Reality catches up later.
What Foundayo Brings to the Table
In ATTAIN-1, patients lost an average of 12.4% of body weight over 36 weeks, compared to 2.0% in the placebo group. The published results describe "a mean percentage change in body weight of −12.4% at week 36 in the orforglipron group." That's a real number. Not the strongest in the class, but for a pill with no food restrictions, it's enough to matter clinically.
Oral Wegovy delivers around 15% average weight loss, meaningfully higher. The tradeoff is a strict empty-stomach requirement every morning, a constraint that works fine for some patients and derails others within the first few months. For patients who tried oral semaglutide and couldn't maintain the routine, or who have irregular schedules, or who travel constantly, Foundayo removes a real barrier. For patients considering injections, tirzepatide is still the strongest approved option by a margin that's hard to argue around.
The Waiting Problem
Every time something new gets approved or makes headlines, the same thing happens. Patients who have been on the fence decide to keep sitting, figuring something even better is around the corner. Sometimes they're right. Usually they're not, and the waiting has costs that don't show up in a press release.
This year that version of the story involves retatrutide. The Phase 3 data is showing average weight loss around 24%, which is higher than anything currently approved. Some patients have decided to wait for the FDA decision, estimated around 2027. A few months into that wait, for some of them, metabolic markers are quietly moving in the wrong direction. The drug they're waiting for won't undo that.
Start with what exists and what fits your life. Adjust when better options arrive. That's how this works.
What's Coming, and What's Worth Watching
Retatrutide (Eli Lilly) is the most interesting candidate in development, by a significant distance. It's a triple agonist, GLP-1, GIP, and glucagon receptors simultaneously, and Phase 3 results in the 24% range would extend the efficacy ceiling well beyond what tirzepatide delivers today. Eli Lilly describes it as targeting "three distinct hormonal pathways involved in energy intake and expenditure." FDA timeline is estimated around 2027, though that date can and usually does move. If the results hold through review, this is the drug that changes the conversation.
Amycretin (Novo Nordisk) is a GLP-1 and amylin combination being developed as both an injection and a pill. Phase 3 trials started in early 2026. The oral version is the development worth watching, if the formulation delivers competitive results without the food restrictions of oral semaglutide, that's meaningful. Timeline is probably 2028-2029 at earliest.
Aleniglipron (Structure Therapeutics) is an oral non-peptide GLP-1 in Phase 2, earlier stage, different molecular approach than orforglipron. Less certain outcome, but part of a broader push toward oral options with higher efficacy ceilings.
None of these are available. Retatrutide is worth following closely. The others are worth knowing about.
What the 2026 Approval Changed in Clinic
The short version of 2026 so far is that the prescribing mix has already shifted. Before Foundayo, patients who wanted oral had one realistic option and it came with a food rule that many could not live with. The alternative was not prescribing at all, or pushing toward an injection they had already said no to. Now there is a second oral on formulary at most pharmacies, and the triage conversation in a new-patient visit takes longer because the options fan out wider than they did six months ago.
A few practical things have surfaced in the first weeks of prescribing this. Patients are tolerating the titration schedule about as well as the trial data suggested they would. The nausea curve in the first month tracks what ATTAIN-1 showed, mild to moderate in most cases, front-loaded, fading by week six or so for most patients. Dose escalation is happening on the expected schedule. None of the early warning signals that sometimes show up post-marketing have surfaced yet, though six weeks is too short to draw any conclusion on that. Long-term safety and durability data will come from patient registries over the next few years.
The insurance story is messier. Most commercial plans have added Foundayo to formulary with prior authorization. Medicare still will not cover any obesity indication, a policy problem that a new approval does not solve, and that forces many older patients to either pay cash or stay on whatever their plan does cover for related conditions. Manufacturer savings programs have helped, and the cash price through direct-to-patient programs is inside the range most patients on injectable GLP-1s are already paying out of pocket.
The Drugs I Am Watching Most Closely
Among the pipeline candidates, three are the ones I check for updates on most weeks. Retatrutide is the big one. Phase 3 data has been landing in waves through 2025 and 2026, and the average weight loss numbers around 24 percent are higher than anything currently approved. If the SURMOUNT-equivalent trials for retatrutide read out cleanly, the FDA decision could come in 2027, and that would move the efficacy ceiling of the whole category up by several points. The mechanism, a triple agonist hitting GLP-1, GIP, and glucagon receptors, is different enough from what is already approved that it may open up response even in patients who did not do well on existing GLP-1s.
Amycretin is the other one I watch. It combines GLP-1 activity with amylin agonism, a pairing that produced Phase 1 numbers in the 22 percent range at high doses. Those were small trials and short, so the Phase 3 numbers may come in lower, but the early signal was strong enough that Novo accelerated it into Phase 3 trials. Estimated approval is 2028 or 2029.
CagriSema sits in between. The NDA was filed in late 2025, Phase 3 data showed roughly 22.7 percent weight loss, and an FDA decision is expected late 2026. It is a meaningful bump over Wegovy but a smaller bump than retatrutide would be, and it comes from a combination of semaglutide and cagrilintide rather than a new mechanism entirely.
Where Things Stand Right Now
2026 has more options than 2025 did. Foundayo is a real addition for a real group of patients. The pipeline is genuinely promising. None of that changes the fact that tirzepatide is still the strongest approved option by the numbers, and that starting something real tends to beat waiting for something theoretical.
If you've been avoiding weight loss medication because injections weren't an option and oral semaglutide's routine didn't fit your life, Foundayo is worth a conversation with your doctor. If you've been waiting for retatrutide, have that conversation now about what exists, and revisit the math when the FDA rules.
